Agilent companion diagnostic expands ce-ivd mark in europe to include triple-negative breast cancer (tnbc)

Santa clara, calif.--(business wire)--agilent technologies inc. (nyse: a) today announced that its pd-l1 ihc 22c3 pharmdx assay is now labelled for use in tnbc in the european union. pd-l1 expression is a critical biomarker for response to anti-pd-1 therapies such as keytruda® (pembrolizumab), an anti-pd-1 therapy manufactured by merck (known as msd outside the united states and canada). the expanded use of pd-l1 ihc 22c3 pharmdx strengthens the ability of pathologists to identify patients who
A Ratings Summary
A Quant Ranking